Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Tom Winnifrith has already stuck the knife into e-Therapeutics (ETX) over its related party deal to re-buy Searchbolt – a company it had previously spun off as non-core (see HERE). Noting the lack of recent accounts, following an extension of its accounting period, there have been no numbers since the period ending July 2014 – figures which were filed very late (14 months post period), and which showed net current assets of MINUS £12,615 and net assets of MINUS £166,078 and £831,528 of losses had been racked up over about seven years (with about £45,000 during the year to July 2014).
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.